APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Apimeds Pharmaceuticals US, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.50−0.54 (-13.37%)
Close on Oct 19, 2026
- Market cap
- $6.00M
- P/E (TTM)
- –
- Dividend yield
- –
Apimeds Pharmaceuticals US statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Market Cap | $5.28M | $164.85M |
| Enterprise Value | $5.00M | $87.06M |
| PB Ratio | 0.05 | 2.03 |
| P/TBV Ratio | 0.05 | 2.31 |
Income (trailing twelve months)
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Operating Income | -$27.35M | -$21.44M |
| Net Income | -$58.17M | -$22.46M |
| EBITDA | -$27.35M | -$16.91M |
| EPS (Diluted) | -$36.69 | -$0.83 |
Returns
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Return on Equity (ROE) | -100.1% | -53.1% |
| Return on Assets (ROA) | -84.2% | -41.0% |
| Return on Invested Capital (ROIC) | -40.3% | -32.0% |
| Return on Capital Employed (ROCE) | -25.7% | -37.8% |
Balance sheet
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $278.37K | $62.42M |
| Net Cash (Debt) | $278.37K | $15.68M |
| Net Cash Per Share | $0.18 | $0.66 |
| Equity (Book Value) | $106.45M | $48.79M |
| Book Value Per Share | $70.54 | $1.36 |
| Tangible Book Value | $106.45M | $23.06M |
| Working Capital | -$10.39M | $75.77M |
Financial position
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Current Ratio | 0.51 | 3.30 |
| Quick Ratio | 0.01 | 2.39 |
| Interest Coverage | -6.35 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Operating Cash Flow | -$13.28M | -$12.35M |
| Capital Expenditures | -$53.36K | -$1.06M |
| Free Cash Flow | -$13.33M | -$20.28M |
| FCF Per Share | -$8.83 | -$0.42 |
Efficiency
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Profits Per Employee | -$6.46M | -$703.34K |
| Employee Count | 9 | 74 |
Dividends and yields
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Earnings Yield | -1101.3% | -22.7% |
| FCF Yield | -252.4% | -9.07% |
Shares
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Shares Outstanding | 1,509,120 | 58,179,650 |
| Shares Change (YoY) | 69.7% | 11.1% |
| Shares Change (QoQ) | 20.0% | 0.54% |
Scores
| Measure | Apimeds Pharmaceuticals US | Industry median |
|---|---|---|
| Altman Z-Score | -1.38 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Apimeds Pharmaceuticals US's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.